Research programme: salmonella-based cancer therapeutics - Tara Immuno-Oncology

Drug Profile

Research programme: salmonella-based cancer therapeutics - Tara Immuno-Oncology

Alternative Names: shIDO ST - Tara Immuno-Oncology; shIDO-ST - Tara immuno-Oncology

Latest Information Update: 07 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Class Antineoplastics; Bacteria
  • Mechanism of Action Fas ligand protein modulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Serine protease modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 03 Nov 2015 Tara Immuno-Oncology in-licenses shIDO ST therapy from The City of Hope National Medical Center
  • 03 Nov 2015 Preclinical trials in Pancreatic cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top